Taiwan
· Delayed Price · Currency is TWD Handa Pharmaceuticals Company Description
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China.
The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules.
It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products.
In addition, the company develops HND-004, a diabetic drug; HND-032 for smoking cessation; and HND-026, a GI drug.
Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
| Country | Taiwan |
| Founded | 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Toshiyo Chen |
Contact Details
Address: No.23, Nanke 3rd Road Tainan City, 74147 Taiwan | |
| Phone | 886 6 505 7508 |
| Website | handapharma.com.tw |
Stock Details
| Ticker Symbol | 6620 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fang-Yu Liu Ph.D. | Founder and Chairman |
| Toshiyo Chen | GM and Director |
| Chi-Yu Yang | Vice President of Finance |
| Dr. Guo-Chun Song Ph.D. | Chief Technology Officer |
| Dr. Zhong-Yi Duan Ph.D. | Vice President of Regulation |
| Mei-Fang Chang Ph.D. | Senior Vice President of Quality Affairs and Director |
| Stephen Douglas Cary M.B.A. | Senior Vice President of Business Development |